Broderick Brian C Boosts Stake in Illumina, Inc. (ILMN)

Broderick Brian C increased its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 0.6% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 13,204 shares of the life sciences company’s stock after buying an additional 75 shares during the period. Illumina comprises approximately 1.5% of Broderick Brian C’s holdings, making the stock its 27th largest holding. Broderick Brian C’s holdings in Illumina were worth $4,102,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the company. Massmutual Trust Co. FSB ADV grew its position in shares of Illumina by 83.0% in the fourth quarter. Massmutual Trust Co. FSB ADV now owns 86 shares of the life sciences company’s stock valued at $26,000 after purchasing an additional 39 shares during the period. First Manhattan Co. grew its position in shares of Illumina by 18.8% in the first quarter. First Manhattan Co. now owns 3,464 shares of the life sciences company’s stock valued at $1,076,000 after purchasing an additional 547 shares during the period. Sapphire Star Partners LP purchased a new stake in shares of Illumina in the fourth quarter valued at $360,000. Machina Capital S.A.S. purchased a new stake in Illumina during the fourth quarter valued at about $1,099,000. Finally, Ardevora Asset Management LLP grew its position in Illumina by 14.2% during the first quarter. Ardevora Asset Management LLP now owns 101,212 shares of the life sciences company’s stock valued at $31,446,000 after acquiring an additional 12,600 shares during the period. Hedge funds and other institutional investors own 90.80% of the company’s stock.

Shares of NASDAQ:ILMN traded up $6.36 during trading on Wednesday, hitting $312.83. The company’s stock had a trading volume of 627,400 shares, compared to its average volume of 976,958. The company has a debt-to-equity ratio of 0.27, a quick ratio of 3.33 and a current ratio of 3.66. Illumina, Inc. has a fifty-two week low of $261.61 and a fifty-two week high of $372.61. The stock has a market cap of $45.22 billion, a price-to-earnings ratio of 54.69, a price-to-earnings-growth ratio of 2.14 and a beta of 1.15.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, April 25th. The life sciences company reported $1.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.34 by $0.26. Illumina had a return on equity of 23.49% and a net margin of 25.06%. The business had revenue of $846.00 million for the quarter, compared to analysts’ expectations of $838.70 million. During the same quarter in the previous year, the firm posted $1.45 earnings per share. The company’s revenue was up 8.2% compared to the same quarter last year. On average, equities research analysts predict that Illumina, Inc. will post 6.68 EPS for the current year.

ILMN has been the subject of a number of research reports. Zacks Investment Research raised Illumina from a “hold” rating to a “buy” rating and set a $339.00 price target for the company in a research report on Friday, February 22nd. Bank of America reissued a “buy” rating and set a $355.00 price target on shares of Illumina in a research report on Wednesday, January 30th. Canaccord Genuity reissued a “buy” rating and set a $350.00 price target (down previously from $360.00) on shares of Illumina in a research report on Friday, April 26th. BidaskClub raised Illumina from a “hold” rating to a “buy” rating in a research report on Tuesday, April 16th. Finally, Deutsche Bank cut Illumina from a “buy” rating to a “hold” rating and set a $296.53 price objective on the stock. in a research note on Friday, January 25th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Illumina currently has an average rating of “Buy” and an average price target of $353.58.

In related news, Director Jay T. Flatley sold 3,300 shares of the business’s stock in a transaction dated Wednesday, February 27th. The stock was sold at an average price of $300.00, for a total value of $990,000.00. Following the completion of the sale, the director now directly owns 341,568 shares of the company’s stock, valued at $102,470,400. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Charles Dadswell sold 124 shares of the business’s stock in a transaction dated Monday, April 1st. The shares were sold at an average price of $314.45, for a total value of $38,991.80. Following the completion of the sale, the senior vice president now directly owns 8,210 shares of the company’s stock, valued at $2,581,634.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 50,329 shares of company stock valued at $15,648,675. 0.38% of the stock is owned by corporate insiders.

TRADEMARK VIOLATION WARNING: This report was first posted by Sundance Herald and is the property of of Sundance Herald. If you are reading this report on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The original version of this report can be read at https://sundanceherald.com/2019/05/22/broderick-brian-c-buys-75-shares-of-illumina-inc-ilmn.html.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as enables the detection of known genetic markers on a single array.

Recommended Story: Purposes and Functions of the Federal Reserve

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply